Skip to main content
Back
Watch Compare

Ovid Therapeutics Inc.

Data quality: 100%
OVID
Nasdaq Manufacturing Chemicals
$2.85
▲ $0.25 (9.62%)
Mkt Cap: 430.43 M
Price
$2.85
Mkt Cap
430.43 M
Day Range
$2.65 — $3.11
52-Week Range
$0.25 — $3.11
Volume
5,294,357
Open $2.68
50D / 200D Avg
$1.85
54.25% above
50D / 200D Avg
$1.36
109.36% above

Quick Summary

Key Takeaways

Negative free cash flow of -38.33 M
Capital efficient — spends only 0.00% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)1181.27%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-34.66%
Above sector avg (-51.02%)
ROIC-53.41%
Net Margin-240.13%
Op. Margin-585.20%

Safety

Debt / Equity
N/A
Current Ratio4.24
Interest CoverageN/A

Valuation

PE (TTM)
-24.72
Below sector avg (-1.98)
P/B Ratio9.63
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (44 peers)
Metric Stock Sector Median
P/E -24.7 -2.0
P/B 9.6 5.1
ROE % -34.7 -51.0
Net Margin % -240.1 -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

ETFs Holding This Stock

BSVO logo BSVO EA Bridgeway Omni Small-Cap Value ETF
0.01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 1181.27% Revenue Growth (3Y) -81.96%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 7.25 M Net Income (TTM) -17.41 M
ROE -34.66% ROA -24.65%
Gross Margin N/A Operating Margin -585.20%
Net Margin -240.13% Free Cash Flow (TTM) -38.33 M
ROIC -53.41% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.24
Interest Coverage N/A Asset Turnover 0.10
Working Capital 22.03 M Tangible Book Value 44.70 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -24.72 Forward P/E N/A
P/B Ratio 9.63 P/S Ratio 59.35
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -8.91%
Market Cap 430.43 M Enterprise Value 409.82 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share 0.05
FCF / Share -0.25 OCF / Share -0.25
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.00% FCF Conversion 220.13%
SBC-Adj. FCF -43.25 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7.25 M 566,000.0 222.80 M 222.50 M —
Net Income -17.41 M -26.43 M -52.34 M -54.17 M 122.83 M
EPS (Diluted) — — -0.74 -0.77 1.76
Gross Profit — — — — —
Operating Income -42.44 M -61.89 M -59.28 M -55.55 M 124.21 M
EBITDA — — — — —
R&D Expenses 25.58 M 36.77 M 28.59 M 24.62 M 46.94 M
SG&A Expenses — — — — —
D&A 273,000.0 613,000.0 568,282.0 512,505.0 237,079.0
Interest Expense — — — — —
Income Tax 0.0 0.0 0.0 0.0 1.33 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 150.93 M 92.17 M 144.03 M 155.27 M 194.54 M
Total Liabilities 20.27 M 23.94 M 56.23 M 22.99 M 14.80 M
Shareholders' Equity 130.66 M 68.23 M 87.80 M 132.27 M 179.75 M
Total Debt — — — — —
Cash & Equivalents 13.15 M 26.30 M 27.04 M 44.87 M 187.80 M
Current Assets 74.37 M 55.94 M 109.60 M 131.38 M 190.48 M
Current Liabilities 8.29 M 10.52 M 11.47 M 6.99 M 14.80 M